$EVOK
Evoke Pharma Inc

2017 Q1 Form 10-Q Financial Statement

#000156459017011039 Filed on May 15, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.210M $1.140M
YoY Change 6.14% 10.68%
% of Gross Profit
Research & Development $770.7K $2.015M
YoY Change -61.75% -16.73%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.980M $3.153M
YoY Change -37.19% -8.49%
Operating Profit -$1.980M -$3.153M
YoY Change -37.19% -8.49%
Interest Expense $964.00 -$72.58K
YoY Change -101.33% -194.2%
% of Operating Profit
Other Income/Expense, Net -$3.072M -$72.58K
YoY Change 4132.27% -3.9%
Pretax Income -$5.050M -$3.230M
YoY Change 56.35% -8.24%
Income Tax
% Of Pretax Income
Net Earnings -$5.052M -$3.225M
YoY Change 56.63% -8.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.37 -$450.5K
COMMON SHARES
Basic Shares Outstanding 13.53M
Diluted Shares Outstanding 13.53M

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.66M $6.100M
YoY Change 140.33% -47.82%
Cash & Equivalents $14.65M $6.100M
Short-Term Investments
Other Short-Term Assets $170.0K $770.0K
YoY Change -77.92% 3159.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.83M $6.870M
YoY Change 115.87% -45.36%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.55K $0.00
YoY Change -100.0%
Total Long-Term Assets $10.00K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $14.83M $6.870M
Total Long-Term Assets $10.00K $0.00
Total Assets $14.84M $6.870M
YoY Change 116.01% -45.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $550.0K $1.240M
YoY Change -55.65% -8.15%
Accrued Expenses $590.0K $480.0K
YoY Change 22.92% 14.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $710.0K
YoY Change -0.41%
Total Short-Term Liabilities $1.140M $2.430M
YoY Change -53.09% -2.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.680M
YoY Change -100.0% -0.22%
Other Long-Term Liabilities $5.770M
YoY Change
Total Long-Term Liabilities $5.770M $3.680M
YoY Change 56.79% -0.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.140M $2.430M
Total Long-Term Liabilities $5.770M $3.680M
Total Liabilities $6.900M $6.120M
YoY Change 12.75% -1.1%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.930M $760.0K
YoY Change
Total Liabilities & Shareholders Equity $14.84M $6.870M
YoY Change 116.01% -45.57%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$5.052M -$3.225M
YoY Change 56.63% -8.39%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.690M -$2.690M
YoY Change -37.17% -10.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.335M $98.74K
YoY Change 7328.04% -81.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.330M 100.0K
YoY Change 7230.0% -81.13%
NET CHANGE
Cash From Operating Activities -1.690M -2.690M
Cash From Investing Activities
Cash From Financing Activities 7.330M 100.0K
Net Change In Cash 5.640M -2.590M
YoY Change -317.76% 4.86%
FREE CASH FLOW
Cash From Operating Activities -$1.690M -$2.690M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1137753
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-72580
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3072747
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1209570
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-72580
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3225409
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7168005
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1980256
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
964
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1980256
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
3152829
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3152829
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
418912
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
10362
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-104184
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-68555
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-275862
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
37379
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1686812
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2690201
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7334739
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
98744
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7334739
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
98744
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5647927
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6099698
CY2016Q1 us-gaap Interest Paid
InterestPaid
62563
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2591457
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8691155
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also relies on contract research organizations (&#8220;CROs&#8221;) to manage and recruit subjects for its clinical trials.&nbsp;&nbsp;If these CROs are unable to continue managing the clinical trials, or are unable to recruit the sufficient number of subjects, the delays could adversely affect the completion of the trials and the timing of the filing of the Company&#8217;s NDA with FDA.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#8217;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet clinical trial supply demand for its product candidate and the development of the product candidate could be materially and adversely affected<font style="font-size:9pt;">.</font></p></div>
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y29D
CY2017Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4773370
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q1 evok Value Of Shares Sold In Prior Twelve Months
ValueOfSharesSoldInPriorTwelveMonths
4800000
CY2017Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
80000
CY2016Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
99000
CY2017Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y9M29D
CY2017Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2017Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2016Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2017Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
50244
CY2016Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
34067
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2600000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2017Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193
CY2017Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.0144
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9419
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0

Files In Submission

Name View Source Status
0001564590-17-011039-index-headers.html Edgar Link pending
0001564590-17-011039-index.html Edgar Link pending
0001564590-17-011039.txt Edgar Link pending
0001564590-17-011039-xbrl.zip Edgar Link pending
evok-10q_20170331.htm Edgar Link pending
evok-20170331.xml Edgar Link completed
evok-20170331.xsd Edgar Link pending
evok-20170331_cal.xml Edgar Link unprocessable
evok-20170331_def.xml Edgar Link unprocessable
evok-20170331_lab.xml Edgar Link unprocessable
evok-20170331_pre.xml Edgar Link unprocessable
evok-ex103_193.htm Edgar Link pending
evok-ex311_192.htm Edgar Link pending
evok-ex312_191.htm Edgar Link pending
evok-ex321_190.htm Edgar Link pending
evok-ex322_189.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending